Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibody
169€ (20 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx344068
tested applications
ELISA, WB, IHC, IF/ICC
Description
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibody is a Rabbit Polyclonal antibody for the detection of Human PCSK9.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) |
| Host | Rabbit |
| Reactivity | Human |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purity | > 95% |
| Purification | Purified by Protein G chromatography. |
| Size 1 | 20 µl |
| Size 2 | 50 µl |
| Size 3 | 100 µl |
| Size 4 | 200 µl |
| Size 5 | 1 ml |
| Form | Liquid |
| Tested Applications | ELISA, WB, IHC, IF/ICC |
| Buffer | 0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q8NBP7 |
| Gene ID | 255738 |
| OMIM | 603776 |
| Alias | FH3,PC9,FHCL3,NARC1,LDLCQ1,NARC-1,HCHOLA3 |
| Background | Antibody anti-PCSK9 |
| Status | RUO |
Descripción
PCSK9 is a serine protease that plays a central role in cholesterol metabolism by regulating the levels of low-density lipoprotein receptors (LDLR) on the cell surface. PCSK9 binds to LDL receptors, promoting their internalization and subsequent degradation in lysosomes, which reduces the uptake of LDL cholesterol (LDL-C) from the bloodstream. Elevated PCSK9 activity leads to hypercholesterolemia and increases the risk of cardiovascular disease due to excessive circulating LDL-C levels. In contrast, loss-of-function mutations in PCSK9 result in reduced LDL receptor degradation, leading to low plasma cholesterol levels and decreased cardiovascular risk. PCSK9 inhibitors, such as monoclonal antibodies (e.g., alirocumab and evolocumab), are highly effective therapies for hypercholesterolemia and cardiovascular disease, as they block PCSK9's activity, preserving LDL receptors on cell surfaces to enhance cholesterol clearance. Beyond lipid metabolism, PCSK9 has been implicated in inflammation, immune regulation, and other pathological processes, making it a versatile target for therapeutic intervention. Its crucial role in cholesterol homeostasis underscores its significance in cardiovascular health and disease management.
Related Products
Guinea pig PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) ELISA Kit
Ver Producto
Human PCSK9 (Proprotein convertase subtilisin/kexin type 9) ELISA Kit
Ver Producto